Organization

START Madrid-CIOCC/University Hospital Sanchinarro

3 abstracts

5 posters

Poster

Phase 2 study of Zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors

Poster

MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

Poster

A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors

Poster

A phase 2 basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors

Poster

MCLA-129-CL01

Abstract

Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL).

Org: START Madrid-CIOCC/University Hospital Sanchinarro, Early Drug Development Group, Division of Medical Oncology, National Cancer Center Singapore, Medical Oncology Department, CatalYm,

Abstract

Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study.

Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, National Cancer Center Hospital East, Kashiwa, Japan, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,

Abstract

Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events.

Org: Gustave Roussy Département d'Organisation du Parcours Patient, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Institut Bergonié, Aix Marseille University - Assistance Publique Hopitaux De Marseille, Université Paris Saclay,